Alpha-synuclein protein clumps — the toxic aggregates related to nerve damage in Parkinson’s disease — vary, including in size, and small fragments appear to drive cellular toxicity compared with larger fragments, a study shows. Its findings were confirmed in post-mortem examinations of brain tissue from Parkinson’s patients, showing smaller clumps…
The risk of developing dementia appears to be higher among people with Parkinson’s disease when compared to age and sex-matched controls, according to the findings of a 25-year follow-up study of more than 1,000 patients in Sweden. The study, “High risk of developing dementia in Parkinson’s disease: a…
Fifty new genes that modified signs of Parkinson’s disease in a fruit fly model have been discovered using a multidisciplinary approach involving genomics, computational tools, and patient sample analysis, a study has reported. Some gene candidates worsened Parkinson’s signs while others conferred neuroprotection, “underscoring their therapeutic potential,” the researchers…
The U.S. Food and Drug Administration (FDA) wants more information before it will approve Supernus Pharmaceuticals’ new drug application (NDA) resubmission of SPN-830, its apomorphine infusion pump. Supernus is seeking the approval of SPN-830 for the continuous treatment of “off” episodes in adults with Parkinson’s disease. These…
People with Parkinson’s disease who show early dysfunction in the nerves controlling heartbeat tend to experience faster disease progression, a new study shows. According to researchers, these results support a new approach differentiating “brain-predominant” Parkinson’s from disease with “body-involvement.” “These findings correspond well to the results of…
Four weeks of physical therapy — specifically, the Lee Silverman Voice Therapy (LSVT)-BIG program — given via telemedicine led to improvements in life quality and symptoms in Parkinson’s disease patients similar to those observed with in-person use of LSVT-BIG, according to a small study. Larger studies of the virtual exercise…
Dosing has begun in LIGHTHOUSE, a Phase 3 clinical trial testing BIIB122 — an experimental inhibitor of LRRK2 being developed by Biogen and Denali Therapeutics — in patients with early-stage Parkinson’s disease. The study (NCT05418673), underway at two clinical sites in Colorado and Florida, is recruiting up…
A research team at the Icahn School of Medicine at Mount Sinai, New York has won the 2022 Parkinson’s Foundation Research Center Award, valued at $2 million, to study the process that results in the selective loss of dopaminergic neurons in Parkinson’s disease. The team, led by…
The pharmaceutical company Kyowa Kirin has unveiled an effort to help educate Parkinson’s disease patients and healthcare professionals about “off” episodes and treatments such as Nourianz (istradefylline), an adjunctive therapy it developed for such times. The new resources ultimately seek to empower adult patients to discuss “off” times…
CENTOGENE has announced it’s reached a milestone of 12,500 participants who have been recruited and genetically tested as part of the Rockstock International Parkinson’s Disease Study (ROPAD), a global observational effort to characterize the genetic profile of Parkinson’s patients. ROPAD (NCT03866603), developed in collaboration with Denali…
Get regular updates to your inbox.
